Zenas BioPharma, Inc. Quarterly Operating Income (Loss) in USD from Q3 2023 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Zenas BioPharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2023 to Q2 2025.
  • Zenas BioPharma, Inc. Operating Income (Loss) for the quarter ending June 30, 2025 was -$55.2M, a 38.9% decline year-over-year.
  • Zenas BioPharma, Inc. Operating Income (Loss) for the twelve months ending June 30, 2025 was -$189M.
  • Zenas BioPharma, Inc. annual Operating Income (Loss) for 2024 was -$164M, a 341% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 -$189M -$55.2M -$15.5M -38.9% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 -$174M -$37.3M -$9.75M -35.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q4 2024 -$164M -$55.6M Oct 1, 2024 Dec 31, 2024 10-K 2025-03-11
Q3 2024 -$41M -$76.6M -215% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$39.7M Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 -$27.6M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q3 2023 $35.6M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.